The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,428.00
Bid: 1,419.00
Ask: 1,422.00
Change: 71.00 (5.23%)
Spread: 3.00 (0.211%)
Open: 1,349.00
High: 1,428.00
Low: 1,349.00
Prev. Close: 1,357.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior Says Former CEO Thaxter's US Sentencing Not Related

Fri, 23rd Oct 2020 10:40

(Alliance News) - Indivior PLC on Friday clarified that the US sentencing of former chief executive Shaun Thaxter for one misdemeanor count is not related to the company.

Shares in the opioid treatment maker were up 0.3% at 100.50 pence each on Friday in London.

Thaxter, who quit as Indivior's boss in July, was sentenced in a US Federal Court on Thursday after pleading guilty to one misdemeanor charge that he caused the company to misrepresent the safety of opioid treatment Suboxone Film in submissions to Massachusetts' Medicaid programme.

The misrepresentations led to the drug being prescribed to patients with children under six-years-old.

Indivior on Friday said: "As the group has previously noted, the plea agreement between Mr Thaxter and the US Department of Justice is in his personal capacity and not on behalf of Indivior. The separate agreement between the group and the government that was announced on July 24 remains unchanged and is subject to approval by a federal judge at a hearing currently scheduled for November 12.

"As previously noted, the incident to which the agreement relates occurred well in the past and does not reflect the values Indivior has strived to demonstrate during its long history of fighting the opioid crisis."

Indivior in July had agreed to pay USD600 million to settle the liabilities over the misrepresentation of the medicine.

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
30 Jun 2021 17:05

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

Read more
30 Jun 2021 13:44

Wednesday broker round-up

(Sharecast News) - Workspace: RBC Capital Markets upgrades to outperform with a target price of 1,050p.

Read more
30 Jun 2021 12:17

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

Read more
30 Jun 2021 10:41

Indivior raises profit and revenue guidance after strong start to year

Indivior raises profit and revenue guidance after strong start to year

Read more
30 Jun 2021 09:02

LONDON MARKET OPEN: Indivior shines after upgrading guidance

LONDON MARKET OPEN: Indivior shines after upgrading guidance

Read more
30 Jun 2021 07:58

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

Read more
30 Jun 2021 07:35

Indivior lifts 2021 guidance after better-than-expected H1

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its 2021 guidance on Wednesday following a better-than-expected business performance through the first half of the year.

Read more
21 Jun 2021 09:34

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

Read more
8 Jun 2021 14:27

IN BRIEF: Indivior secures license for cannabis disorder treatment

IN BRIEF: Indivior secures license for cannabis disorder treatment

Read more
8 Jun 2021 12:36

Indivior joins forces with France's Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
8 Jun 2021 12:36

Indivior teams up with Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
6 May 2021 17:50

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

Read more
29 Apr 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
29 Apr 2021 12:26

Indivior maintains 2021 guidance as first quarter revenue increases

Indivior maintains 2021 guidance as first quarter revenue increases

Read more
28 Apr 2021 10:47

Indivior says US filings "administrative", no new Suboxone settlements

Indivior says US filings "administrative", no new Suboxone settlements

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.